Start-Up Previews (7/06)
A preview of the emerging health care companies profiled in the current, all profiles issue of Start-Up. This month's profile groups: Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology, Neurostimulation's Billion Dollar Markets, and Antibacterial Drug Development. Plus these Start-Up Across Health Care: Ascenta Therapeutics, CircuLite, CoroNovative and Endovalve.
You may also be interested in...
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
She is as polarizing as she is powerful, but whether you think Janet Woodcock is drug development’s hero or public health’s enemy, there’s no denying she dramatically transformed the US FDA over her 35-year career.
Personal-care and beauty products can do without fragrances that contain phthalates, says Washington Department of Ecology in a November Draft Regulatory Determinations Report to state lawmakers as per the Safer Products for Washington Act. Restriction specifics will be worked out in 2022 in consultation with stakeholders, Ecology says.